7Baggers
 Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y  Yahoo Finance Tue, 11 Nov 2025 15:37:00 GMT
 Editas Medicine (NASDAQ:EDIT) Announces Earnings Results  MarketBeat Tue, 11 Nov 2025 14:16:25 GMT
 truist financial maintains editas medicine(edit.us) with hold rating  富途牛牛 Tue, 11 Nov 2025 13:31:00 GMT
 Editas Medicine Reports Q3 2025 Progress and Financials  TipRanks Tue, 11 Nov 2025 04:49:59 GMT
 editas medicine (edit) pt raised to $4.60 at clear street  StreetInsider Mon, 10 Nov 2025 23:55:06 GMT
 Editas Medicine reports Q3 EPS (28c), consensus (38c)  TipRanks Mon, 10 Nov 2025 15:54:56 GMT
 Editas Medicine earnings beat by $0.02, revenue topped estimates  Investing.com Mon, 10 Nov 2025 13:22:54 GMT
 editas medicine (edit) tops q3 eps by 2c  StreetInsider Mon, 10 Nov 2025 12:34:37 GMT
 editas medicine q3 net loss narrows, beats expectations  TradingView Mon, 10 Nov 2025 12:08:35 GMT
 editas medicine unveils edit-401 data at aha 2025  Traders Union Mon, 03 Nov 2025 14:16:13 GMT
 Editas Medicine Announces EDIT-401 Poster Presentation at  GlobeNewswire Mon, 03 Nov 2025 08:00:00 GMT

Editas Medicine, Inc
(NASDAQ:EDIT) 

EDIT stock logo

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. ...

Founded: 2013
Full Time Employees: 208
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends